candesartan has been researched along with Brain Edema in 8 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Brain Edema: Increased intracellular or extracellular fluid in brain tissue. Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see HYPOXIA, BRAIN). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of CSF flow (e.g., obstructive HYDROCEPHALUS). (From Childs Nerv Syst 1992 Sep; 8(6):301-6)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Neurovascular protection against cerebral ischemia is not consistently observed with a postischemia hypotensive dose of candesartan." | 7.77 | Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia. ( Fu, H; Hosomi, N; Itano, T; Kohno, M; Liu, G; Masugata, H; Matsumoto, M; Miki, T; Nakano, D; Nishiyama, A; Pelisch, N; Sueda, Y; Ueno, M, 2011) |
| "To determine whether BP lowering with candesartan, initiated at reperfusion, can reduce neurovascular damage and improve outcome in a model of hypertension after experimental ischemic stroke." | 7.73 | Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection. ( Ergul, A; Fagan, SC; Hess, DC; Hill, WD; Johnson, MH; Kozak, A; Pollock, DM; Xu, L, 2006) |
| "Candesartan treatment normalized blood pressure and the shift toward higher blood pressures at both the upper and lower limits of cerebrovascular autoregulation in SHR." | 5.31 | Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. ( Ito, T; Nishimura, Y; Saavedra, JM, 2000) |
| "Neurovascular protection against cerebral ischemia is not consistently observed with a postischemia hypotensive dose of candesartan." | 3.77 | Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia. ( Fu, H; Hosomi, N; Itano, T; Kohno, M; Liu, G; Masugata, H; Matsumoto, M; Miki, T; Nakano, D; Nishiyama, A; Pelisch, N; Sueda, Y; Ueno, M, 2011) |
| "To determine whether BP lowering with candesartan, initiated at reperfusion, can reduce neurovascular damage and improve outcome in a model of hypertension after experimental ischemic stroke." | 3.73 | Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection. ( Ergul, A; Fagan, SC; Hess, DC; Hill, WD; Johnson, MH; Kozak, A; Pollock, DM; Xu, L, 2006) |
| "Candesartan (0·05 mg/kg) was administered just after initiation of ischaemia followed by a repeat administration at 24 h while 1, 5 isoquinolinediol (0·1 mg/kg) was given one-hour after of ischaemia." | 1.40 | A comparative study of neuroprotective effect of single and combined blockade of AT1 receptor and PARP-1 in focal cerebral ischaemia in rat. ( Hanif, K; Sharma, G; Singh, N, 2014) |
| "Focal cerebral ischemia, induced by middle cerebral artery occlusion/reperfusion (MCAO), was conducted at 4 wk after STZ injection." | 1.32 | Role of AT1 receptors and NAD(P)H oxidase in diabetes-aggravated ischemic brain injury. ( Granger, DN; Ishikawa, M; Kusaka, G; Kusaka, I; Nanda, A; Tang, J; Zhang, JH; Zhou, C, 2004) |
| "Candesartan treatment normalized blood pressure and the shift toward higher blood pressures at both the upper and lower limits of cerebrovascular autoregulation in SHR." | 1.31 | Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. ( Ito, T; Nishimura, Y; Saavedra, JM, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Panahpour, H | 1 |
| Nekooeian, AA | 1 |
| Dehghani, GA | 1 |
| Fu, H | 1 |
| Hosomi, N | 1 |
| Pelisch, N | 1 |
| Nakano, D | 1 |
| Liu, G | 1 |
| Ueno, M | 1 |
| Miki, T | 1 |
| Masugata, H | 1 |
| Sueda, Y | 1 |
| Itano, T | 1 |
| Matsumoto, M | 1 |
| Nishiyama, A | 1 |
| Kohno, M | 1 |
| Singh, N | 2 |
| Sharma, G | 1 |
| Hanif, K | 1 |
| Yamakawa, H | 1 |
| Jezova, M | 1 |
| Ando, H | 1 |
| Saavedra, JM | 2 |
| Kusaka, I | 1 |
| Kusaka, G | 1 |
| Zhou, C | 1 |
| Ishikawa, M | 1 |
| Nanda, A | 1 |
| Granger, DN | 1 |
| Zhang, JH | 1 |
| Tang, J | 1 |
| Fagan, SC | 1 |
| Kozak, A | 1 |
| Hill, WD | 1 |
| Pollock, DM | 1 |
| Xu, L | 1 |
| Johnson, MH | 1 |
| Ergul, A | 1 |
| Hess, DC | 1 |
| Brdon, J | 1 |
| Kaiser, S | 1 |
| Hagemann, F | 1 |
| Zhao, Y | 1 |
| Culman, J | 1 |
| Gohlke, P | 1 |
| Nishimura, Y | 1 |
| Ito, T | 1 |
8 other studies available for candesartan and Brain Edema
| Article | Year |
|---|---|
Candesartan attenuates ischemic brain edema and protects the blood-brain barrier integrity from ischemia/reperfusion injury in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood-Brain Ba | 2014 |
Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Benzimidazoles; B | 2011 |
A comparative study of neuroprotective effect of single and combined blockade of AT1 receptor and PARP-1 in focal cerebral ischaemia in rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Brain; Brain E | 2014 |
Normalization of endothelial and inducible nitric oxide synthase expression in brain microvessels of spontaneously hypertensive rats by angiotensin II AT1 receptor inhibition.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Arterial Occlusive Diseases; Ben | 2003 |
Role of AT1 receptors and NAD(P)H oxidase in diabetes-aggravated ischemic brain injury.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Blood Pressure; | 2004 |
Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection.
Topics: Animals; Antihypertensive Agents; Behavior, Animal; Benzimidazoles; Biphenyl Compounds; Blood Pressu | 2006 |
Comparison between early and delayed systemic treatment with candesartan of rats after ischaemic stroke.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2007 |
Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 2000 |